TYK2 Inhibition: Evolving Options in Psoriasis Care - Episode 6
Selectivity of TYK2 Inhibition in Psoriasis
Published on:
Next-generation TIC-2 inhibitors show remarkable selectivity, enhancing efficacy while minimizing side effects, offering insights into immune system safety.
Panelists discuss the questions below in this video.
How does the selectivity of TYK2 inhibition differ from JAK inhibition?
At what level of pathway inhibition (% inhibition of IL-12, IL-23, IFN) do we see efficacy without safety liabilities, and how narrow or wide is this therapeutic window compared to JAK inhibitors?
Loss-of-function TYK2 variants have been linked to protection from psoriasis. How do these genetic findings inform our understanding of TYK2’s role and support selective inhibition as a therapeutic strategy?
